Association of oxidative DNA damage and C-reactive protein in women at risk for cardiovascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2776-2784

  Noren Hooten, Nicole ^a   Ejiogu, Ngozi ^a   Zonderman, Alan B ^a   Evans, Michele K ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

8 oxo 7,8 dihydro 2'deoxyguanosine; C reactive protein; Cardiovascular disease; DNA damage; Inflammation; Oxidative stress; Women's health

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P70; INTERLEUKIN 23; 8 OXO 7 HYDRODEOXYGUANOSINE; 8-OXO-7-HYDRODEOXYGUANOSINE; AUTACOID; BIOLOGICAL MARKER; DEOXYGUANOSINE; DRUG DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; ENDOTHELIUM CELL; FEMALE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PULSE PRESSURE; SINGLE STRANDED DNA BREAK; SYSTOLIC BLOOD PRESSURE; CELL CULTURE; GENETICS; IMMUNOLOGY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; UMBILICAL VEIN ENDOTHELIAL CELL; UNITED STATES;

ADULT; BALTIMORE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CELLS, CULTURED; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MIDDLE AGED; ODDS RATIO; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 84871880340     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300276     Document Type: Article

References (49)

1. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and infammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol. 2003;23:1398-1404.
2. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombo-sis. Circulation. 2006;113:2135-50; discussion 2150.
3. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo signifcance. Arterioscler Thromb Vasc Biol. 2008;28:698-704.
4. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006;113:2128-34; discussion 2151.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
6. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.
7. Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242:237-239.
8. Chen C, Nan B, Lin P, Yao Q. C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. Thromb Res. 2008;122:125-133.
9. Shishehbor MH, Hazen SL. Infammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep. 2004;6:243-250.
10. D'Autréaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specifcity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8:813-824.
11. Andreassi MG. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutat Res. 2003;543:67-86.
12. Gray K, Bennett M. Role of DNA damage in atherosclerosis-bystander or participant? Biochem Pharmacol. 2011;82:693-700.
13. Trzeciak AR, Mohanty JG, Jacob KD, Barnes J, Ejiogu N, Lohani A, Zonderman AB, Rifkind JM, Evans MK. Oxidative damage to DNA and single strand break repair capacity: Relationship to other measures of oxidative stress in a population cohort. Mutat Res. 2012;736:93-103.
14. Shin CS, Moon BS, Park KS, Kim SY, Park SJ, Chung MH, Lee HK. Serum 8-hydroxy-guanine levels are increased in diabetic patients. Diabetes Care. 2001;24:733-737.
15. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis. 2002;9:244-248.
16. Evans MD, Cooke MS, Akil M, Samanta A, Lunec J. Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Commun. 2000;273:894-898.
17. Haghdoost S, Maruyama Y, Pecoits-Filho R, Heimburger O, Seeberger A, Anderstam B, Suliman ME, Czene S, Lindholm B, Stenvinkel P, Harms-Ringdahl M. Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic infammation? Antioxid Redox Signal. 2006;8:2169-2173.
18. Cooke MS, Olinski R, Evans MD. Does measurement of oxidative damage to DNA have clinical signifcance? Clin Chim Acta. 2006;365:30-49.
19. De Flora S, Izzotti A, Walsh D, Degan P, Petrilli GL, Lewtas J. Molecular epidemiology of atherosclerosis. FASEB J. 1997;11:1021-1031.
20. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation. 2002;106:927-932.
21. Collins AR, Gedik CM, Olmedilla B, Southon S, Bellizzi M. Oxidative DNA damage measured in human lymphocytes: large differences between sexes and between countries, and correlations with heart disease mortality rates. FASEB J. 1998;12:1397-1400.
22. Mason PJ, Manson JE, Sesso HD, Albert CM, Chown MJ, Cook NR, Greenland P, Ridker PM, Glynn RJ. Blood pressure and risk of secondary cardiovascular events in women: the Women's Antioxidant Cardiovascular Study (WACS). Circulation. 2004;109:1623-1629.
23. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of infammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
24. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem. 2004;50:574-581.
25. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464-469.
26. Wenger NK. Coronary heart disease in men and women: does 1 size ft all? No! Clin Cardiol. 2011;34:663-667.
27. Evans MK, Lepkowski JM, Powe NR, LaVeist T, Kuczmarski MF, Zonderman AB. Healthy aging in neighborhoods of diversity across the life span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status. Ethn Dis. 2010;20:267-275.
28. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, Hiai H, Ochi H, Osawa T. Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest. 1997;76:365-374.
29. Noren Hooten N, Kompaniez K, Barnes J, Lohani A, Evans MK. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1). J Biol Chem. 2011;286:44679-44690.
30. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
31. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22:1668-1673.
32. Kuhlmann CR, Librizzi L, Closhen D, Pfanzner T, Lessmann V, Pietrzik CU, de Curtis M, Luhmann HJ. Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke. 2009;40:1458-1466.
33. Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular system.-Review and perspective-. Circ J. 2011;75:1791-1800.
34. Streeter J, Thiel W, Brieger K, Miller Jr FJ. Opportunity Nox: the Future of NADPH Oxidases as Therapeutic Targets in Cardiovascular Disease. Cardiovasc Ther. 2012;00:1-13.
35. TakCac I, Schröder K, Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep. 2012;14:70-78.
36. Bhakat KK, Mokkapati SK, Boldogh I, Hazra TK, Mitra S. Acetylation of human 8-oxoguanine-DNA glycosylase by p300 and its role in 8-oxo-guanine repair in vivo. Mol Cell Biol. 2006;26:1654-1665.
37. de Souza-Pinto NC, Maynard S, Hashiguchi K, Hu J, Muftuoglu M, Bohr VA. The recombination protein RAD52 cooperates with the excision repair protein OGG1 for the repair of oxidative lesions in mammalian cells. Mol Cell Biol. 2009;29:4441-4454.
38. Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem. 1997;272:19633-19636.
39. Binková B, Smerhovský Z, Strejc P, Boubelík O, Stávková Z, Chvátalová I, Srám RJ. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat Res. 2002;501:115-128.
40. Binková B, Strejc P, Boubelík O, Stávková Z, Chvátalová I, Srám RJ. DNA adducts and human atherosclerotic lesions. Int J Hyg Environ Health. 2001;204:49-54.
41. Ohtsubo T, Ohya Y, Nakamura Y, Kansui Y, Furuichi M, Matsumura K, Fujii K, Iida M, Nakabeppu Y Accumulation of 8-oxo-deoxyguanosine in cardiovascular tissues with the development of hypertension. DNA Repair (Amst). 2007;6:760-769.
42. Inoue T, Inoue K, Maeda H, Takayanagi K, Morooka S. Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL concentrations in dyslipidemic patients. Clin Chim Acta. 2001;305:115-121.
43. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18:1018-1028.
44. Komoda H, Inoue T, Node K. Anti-infammatory properties of azel-nidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010;32:121-128.
45. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelni-dipine decreases plasma infammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008;31:1147-1155.
46. Gackowski D, Kruszewski M, Jawien A, Ciecierski M, Olinski R. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med. 2001;31:542-547.
47. Cooke MS, Olinski R, Loft S; European Standards Committee on Urinary (DNA) Lesion Analysis. Measurement and meaning of oxida-tively modifed DNA lesions in urine. Cancer Epidemiol Biomarkers Prev. 2008;17:3-14.
48. Evans MD, Olinski R, Loft S, Cooke MS; European Standards Committee on Urinary (DNA) Lesion Analysis. Toward consensus in the analysis of urinary 8-oxo-7, 8-dihydro-2'-deoxyguanosine as a noninvasive biomarker of oxidative stress. FASEB J. 2010;24:1249-1260.
49. Simm A, Nass N, Bartling B, Hofmann B, Silber RE, Navarrete Santos A. Potential biomarkers of ageing. Biol Chem. 2008;389:257-265.